Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

TapImmune Recognizes National Breast Cancer Awareness Month With Renewed Urgency to Develop Cancer Vaccines

By PR Newswire | October 4, 2016

(Photo credit: James Palinsad; https://www.flickr.com/photos/99329675@N02/11064787385)

TapImmune, Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, is celebrating the month of October by reinforcing its efforts to prevent and cure breast and ovarian cancer.

In an open letter posted on the TapImmune website, the company’s Chairman and CEO, Glynn Wilson, Ph. D, paid tribute to friends and loved one’s who have been affected by cancer during National Breast Cancer Awareness Month.

Breast cancer is the most common cancer among women in the United States. Every two minutes a woman in the U.S. is diagnosed with breast cancer and approximately 40,500 are expected to die this year from the disease.

According to Wilson, over the past year there has been growing evidence that the approach of immuno-oncology, that stimulates the body’s own immune system, will be a major force in the treatment of breast cancer.

TapImmune is making important progress in its development of T-cell vaccines for the treatment of breast and ovarian with the initiation of multiple Phase II clinical trials to determine the efficacy of its vaccines. The company’s Phase II clinical trial in triple negative breast cancer is recruiting a total of 80 patients at eight different clinical centers in the U.S. and the first patients have already been treated.

“Immuno- therapy is now perceived in the medical community as the most promising treatment for cancer,” said Glynn Wilson, Ph. D, Chairman and CEO, TapImmune. “We are proud to be at the forefront of immuno-oncology for breast cancer treatment and we are encouraged by our recent clinical progress. For us, we start National Breast Cancer Awareness Month in 2016 with renewed purpose towards our ultimate goal to save lives in indications that are in great need of new therapies.”

To view the full press release, click here. 

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE